Inactive Instrument

Analyst Reco. Aravive, Inc.

Equities

Cantor Fitzgerald Downgrades Aravive to Neutral From Overweight, Adjusts Price Target to $0.25 From $18	22/08/23	MT
EF Hutton Downgrades Aravive to Hold From Buy, Adjusts Price Target to $1 From $10	03/08/23	MT
HC Wainwright Downgrades Aravive to Neutral From Buy	03/08/23	MT
William Blair Downgrades Aravive to Market Perform From Outperform	03/08/23	MT
BTIG Downgrades Aravive to Neutral From Buy	03/08/23	MT
BTIG Adjusts Price Target on Aravive to $9 From $12, Maintains Buy Rating	10/07/23	MT
HC Wainwright Raises Price Target on Aravive to $12 From $7, Maintains Buy Rating	16/03/23	MT
EF Hutton Starts Aravive at Buy With $10 Price Target	05/01/23	MT
Piper Sandler Trims Price Target on Aravive to $2 From $6, Keeps Overweight Rating	14/11/22	MT
Roth Capital Adjusts Price Target on Aravive to $10 From $15, Reiterates Buy Rating	28/10/22	MT
HC Wainwright Cuts Price Target on Aravive to $7 From $26, Keeps Buy Rating	25/10/22	MT
Roth Capital Initiates Aravive at Buy with $15 Price Target	03/06/22	MT
Piper Sandler Adjusts Aravive's Price Target to $6 From $9, Reiterates Overweight Rating	13/05/22	MT
Aravive Says Renal Cell Cancer Drug Showed 46% Overall Response Rate in Phase 1b Study	03/03/22	MT
ARAVIVE : Piper Sandler Adjusts Aravive's Price Target to $18 From $20, Maintains Overweight Rating	06/08/21	MT
ARAVIVE : BTIG Initiates Aravive at Buy Rating With $26 Price Target	08/03/21	MT
ARAVIVE : Wedbush Adjusts Aravive's PT to $15 From $24 on Market Penetration Forecast for AVB-500/Ovarian Cancer; Outperform Rating Kept	09/11/20	MT

No results for this search